Tumor-specific immune responses.
作者信息
Schreiber Hans
出版信息
Semin Immunol. 2008 Oct;20(5):265-6. doi: 10.1016/j.smim.2008.10.001. Epub 2008 Nov 1.
Abstract
摘要
相似文献
1
Tumor-specific immune responses.肿瘤特异性免疫反应。
Semin Immunol. 2008 Oct;20(5):265-6. doi: 10.1016/j.smim.2008.10.001. Epub 2008 Nov 1.
2
Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments.实体瘤的当代免疫疗法：从肿瘤相关抗原到联合治疗
Curr Opin Drug Discov Devel. 2010 Mar;13(2):184-92.
3
Mechanism of action of immunotherapy.免疫疗法的作用机制。
Semin Oncol. 2014 Oct;41 Suppl 5:S3-13. doi: 10.1053/j.seminoncol.2014.09.004. Epub 2014 Sep 6.
4
Cellular and humoral immune responses of cancer patients to defined tumor antigens.癌症患者对特定肿瘤抗原的细胞免疫和体液免疫反应。
Cancer Chemother Biol Response Modif. 2001;19:385-93.
5
Immune surveillance and anti-tumor immune responses: an anatomical perspective.免疫监视与抗肿瘤免疫反应：解剖学视角
Immunol Lett. 2005 Apr 15;98(1):1-8. doi: 10.1016/j.imlet.2004.09.005.
6
Tumor vaccine: current trends in antigen specific immunotherapy.肿瘤疫苗：抗原特异性免疫疗法的当前趋势
Indian J Exp Biol. 2005 May;43(5):389-406.
7
Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.独特的肿瘤抗原：基因组完整性免疫控制的证据及T细胞介导的患者特异性免疫治疗的免疫原性靶点
Clin Cancer Res. 2006 Sep 1;12(17):5023-32. doi: 10.1158/1078-0432.CCR-05-2682.
8
[The function of tumor specific antigen (MAGE) in tumor immunotherapy].[肿瘤特异性抗原（MAGE）在肿瘤免疫治疗中的作用]
Sheng Li Ke Xue Jin Zhan. 2005 Jul;36(3):273-5.
9
[Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].[肿瘤免疫学展望：恶性疾病的抗原特异性免疫疗法]
Dtsch Med Wochenschr. 2001 Sep 14;126(37):1011-6. doi: 10.1055/s-2001-17111.
10
The complexity of unique tumor-specific antigens.独特肿瘤特异性抗原的复杂性。
Symp Fundam Cancer Res. 1986;38:161-82.
引用本文的文献
1
Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.肿瘤微环境调节溶瘤腺病毒联合 GSK-3β 抑制剂增强膀胱癌的抗肿瘤免疫反应。
Front Immunol. 2024 May 15;15:1360436. doi: 10.3389/fimmu.2024.1360436. eCollection 2024.
2
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).用于嵌合抗原受体 (CAR) 和双特异性 T 细胞衔接器 (BiTE) 靶向 T 细胞的敏感性量表。
Oncoimmunology. 2012 Sep 1;1(6):863-873. doi: 10.4161/onci.20592.
本文引用的文献
1
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.癌前病变的免疫原性是导致一般细胞毒性T淋巴细胞无反应性的主要原因。
J Exp Med. 2008 Jul 7;205(7):1687-700. doi: 10.1084/jem.20072016. Epub 2008 Jun 23.
2
Epitope landscape in breast and colorectal cancer.乳腺癌和结直肠癌中的表位图谱。
Cancer Res. 2008 Feb 1;68(3):889-92. doi: 10.1158/0008-5472.CAN-07-3095.
3
Characterizing the cancer genome in lung adenocarcinoma.表征肺腺癌中的癌症基因组。
Nature. 2007 Dec 6;450(7171):893-8. doi: 10.1038/nature06358. Epub 2007 Nov 4.
4
The genomic landscapes of human breast and colorectal cancers.人类乳腺癌和结直肠癌的基因组图谱。
Science. 2007 Nov 16;318(5853):1108-13. doi: 10.1126/science.1145720. Epub 2007 Oct 11.
5
From morphological to molecular diagnosis of soft tissue tumors.从软组织肿瘤的形态学到分子诊断
Adv Exp Med Biol. 2006;587:99-113. doi: 10.1007/978-1-4020-5133-3_10.
6
Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.技术洞察：新兴免疫治疗策略在爱泼斯坦-巴尔病毒相关恶性肿瘤中的应用
Nat Clin Pract Oncol. 2005 Mar;2(3):138-49. doi: 10.1038/ncponc0107.
7
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.散发性免疫原性肿瘤通过诱导T细胞耐受来避免被破坏。
Nature. 2005 Sep 1;437(7055):141-6. doi: 10.1038/nature03954.
8
9
Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.肉瘤相关染色体易位融合蛋白的抗原性
Cancer Res. 2001 Sep 15;61(18):6868-75.
10
Unique tumor antigens redefined as mutant tumor-specific antigens.独特肿瘤抗原被重新定义为突变型肿瘤特异性抗原。
Semin Immunol. 1996 Oct;8(5):289-93. doi: 10.1006/smim.1996.0037.
Zotero 插件